Prescient Therapeutics Limited
OTC: PSTTF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven Lee Yatomi-Clarke
- Headquarters
- Melbourne, Australia
- IPO year
- 2017
- Market cap
- $117.5M
- Website
- https://ptxtherapeutics.com
Loading PSTTF…
Loading profile data…Frequently asked questions about PSTTF
What does Prescient Therapeutics Limited (PSTTF) do?
Operating from Melbourne, Australia, Prescient Therapeutics Limited is a clinical-stage oncology company dedicated to pioneering novel pharmaceutical treatments for a variety of cancers. The company's primary investigational therapy, PTX-200, is currently undergoing several advanced clinical trials: a Phase 2a study for HER2-negative breast canc...
Where does PSTTF trade?
Prescient Therapeutics Limited (PSTTF) trades on the Other OTC.
What sector is PSTTF in?
Prescient Therapeutics Limited (PSTTF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Prescient Therapeutics Limited?
Steven Lee Yatomi-Clarke is the chief executive officer of Prescient Therapeutics Limited (PSTTF).
Where is Prescient Therapeutics Limited headquartered?
Prescient Therapeutics Limited is headquartered in Australia.
Does PSTTF pay a dividend?
Prescient Therapeutics Limited (PSTTF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PSTTF go public?
Prescient Therapeutics Limited (PSTTF) completed its initial public offering in 2017.